Project Grant R41CA291354
Award Date
9/4/24
Completion Date
8/31/25
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Belle Mead, Montgomery, NJ, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,623,261 to Case Western Reserve University to conduct a clinical trial and develop novel molecular technologies for early detection and prevention of esophageal adenocarcinoma. Specifically, the project aims to: 1) demonstrate the efficacy of a non-endoscopic, biomarker-based approach to detect Barrett's esophagus, a precursor to esophageal cancer, in a population...
This $370,575 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to identify DNA methylation biomarkers for adenoid cystic carcinoma (ACC), a common salivary gland cancer. The key objectives are to: Examine DNA methylation and transcriptomic profiles of 200 clinically annotated ACC tumors to refine subtyping and prognosis. Profile methylation/transcriptome of paired primary and metastatic ACC...
The National Cancer Institute (NCI) awarded a $230,010 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Chicago to develop and apply a new epigenome sequencing platform called Glycosylase-Implemented Epigenome Sequencing (GLIMP-SEQ). This platform is designed to enable highly sensitive and specific profiling of 5-methylcytosine (5mC) in degraded clinical samples such as formalin-fixed, paraffin-embedded (FFPE) tissues and cell-free DNA (cfDNA). The grant aims to...
The National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded an $821,797 Project Grant to Early IS Good, Inc. to execute a clinical validation study for their BCDX bladder cancer diagnostic assay. BCDX uses advanced nanotechnology to detect 12 different biomarkers directly from a urine sample, providing a comprehensive, multi-omic, and multiplex approach to bladder cancer detection and recurrence monitoring. The 2-year project aims...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business in Palo Alto, California. The grant supports the development of a novel assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using orphan non-coding RNA (oncRNA) biomarkers. The goal is to create a liquid biopsy-based diagnostic...
The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
The National Cancer Institute (NCI) awarded a $386,700 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the Regents of the University of Minnesota. The grant, titled "Preclinical Development and Validation of Targeted Mass Spectrometry Assays for Serous Ovarian Cancer Diagnosis", will fund research to develop and validate novel multiplexed protein biomarker assays that can differentiate serous ovarian cancer patients from healthy individuals. The...
This $2,136,715 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is focused on harnessing DNA methylation in peripheral blood to improve colorectal cancer prevention. The primary awardee, President and Fellows of Harvard College through its Harvard T.H. Chan School of Public Health, will lead the research effort. Key sub-awards have been made to Dana-Farber Cancer Institute and Boston University to contribute...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,280,475.00 to The Leland Stanford Junior University to develop a novel approach for early detection of colorectal cancer using cell-free DNA (cfDNA) methylation profiles. The key objectives are to: (1) characterize the early-stage colorectal cancer cfDNA methylome landscape, and (2) develop a machine learning model to detect early-stage colorectal cancer from...
The National Cancer Institute (NCI) awarded a $564,414 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant will fund a 5-year research project to: 1) Develop and validate a predictive model based on electronic health record data that can accurately identify individuals at high risk for gastric cancer, and 2) Develop a mathematical model to assess the potential...